FUSN Nasdaq

Fusion Pharmaceuticals Inc.

FUSN | $21.325 0.31% 0.3% 350K

(0.0% 1d) (0.7% 1m) (459.6% 1y) (0.0% 2d) (0.0% 3d) (0.4% 7d) (-21.16% volume)
Earnings Calendar: 2024-03-14
Market Cap: $ 1,809,746,573
http://www.fusionpharma.com
Sec Filling | Patents | 40 employees

Fusion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It develops GMP manufacturing of radiopharmaceuticals for the diagnosis and treatment of disease. The company was founded by John Vaillant and is headquartered in Hamilton, Canada.

diagnostics msa treatment

add to watch list Paper trade email alert is off

Press-releases

Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - prnewswire.com
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| -0.28% | O: -0.19% H: 0.28% C: 0.09%
fpi-2265 presentation pharmaceuticals meeting trial

Monteverde & Associates PC and Kahn Swick & Foti LLC Announce Proposed Class Action Settlement on Behalf of All Owners of Harvest Capital Credit Corporation Common Stock
Published: 2024-03-27 (Crawled : 23:00) - prnewswire.com
PTMN | $19.33 0.78% 0.78% 15K

Finance

| 3.64% | O: -0.11% H: 1.66% C: 1.61%
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 0.09% | O: 0.0% H: 0.33% C: 0.09%
harvest corporation

INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN
Published: 2024-03-26 (Crawled : 00:00) - prnewswire.com
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 0.09% | O: -0.14% H: 0.38% C: 0.14%
pharmaceuticals

INVESTIGATION ALERT: Halper Sadeh LLC Investigates LABP, FUSN, KNTE
Published: 2024-03-25 (Crawled : 20:00) - prnewswire.com
LABP | $21.705 -0.53% -0.53% 13K

| 1.34% | O: -0.09% H: 0.69% C: -0.42%
ABBV | News | $167.89 0.89% 0.0% 5.6M

Health Technology

| -5.96% | O: 0.39% H: 0.3% C: -0.02%
XOMA | $25.61 0.51% 0.51% 7.2K

Health Technology

| 7.58% | O: 0.04% H: 0.0% C: -3.58%
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 0.66% | O: 0.38% H: 0.28% C: 0.19%

Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Published: 2024-03-20 (Crawled : 20:00) - prnewswire.com
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 1.09% | O: 0.09% H: 0.43% C: 0.43%
year pharmaceuticals program financial results

Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Published: 2024-03-19 (Crawled : 07:00) - prnewswire.com
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 100.38% | O: 96.99% H: 1.19% C: 1.05%
cancer treat pharmaceuticals acquired

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
Published: 2024-03-19 (Crawled : 12:00) - biospace.com/
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 100.38% | O: 96.99% H: 1.19% C: 1.05%
AZN | News | $70.12 2.29% 2.24% 4.8M

Health Technology

| 6.5% | O: -0.38% H: 0.46% C: 0.4%
astrazeneca cancer treat acquire

Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 6, 2024
Published: 2024-03-06 (Crawled : 17:00) - biospace.com/
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 103.05% | O: 1.33% H: 2.16% C: -6.95%
nasdaq pharmaceuticals grants

Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
Published: 2024-03-05 (Crawled : 22:00) - prnewswire.com
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 103.05% | O: 1.33% H: 2.16% C: -6.95%
fpi-2265 pharmaceuticals meeting trial

Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
Published: 2024-02-26 (Crawled : 16:00) - biospace.com/
FUSN | $21.325 0.31% 0.3% 350K

Health Technology

| 75.62% | O: 0.25% H: 7.71% C: 3.94%
pharmaceuticals

See all